Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Relapsed/Refractory HER2+ MBC Treatment Decisions

July 27th 2021

Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.

FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC Plus Chemo as Neoadjuvant Treatment, Then as Single-Agent Adjuvant Treatment

July 27th 2021

The FDA has approved pembrolizumab for the treatment of patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.

Individualized Treatment Decisions for HER2+ Breast Cancer

July 27th 2021

Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.

Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment Algorithm

July 26th 2021

William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.

Roche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe

July 26th 2021

Roche Registration GmbH has withdrawn its application to extend the use of atezolizumab to the treatment of patients with early or locally advanced triple-negative breast cancer in Europe.

Dr. Carey on the ​Results of the monarchE Trial in HR+/HER2- Breast Cancer

July 22nd 2021

Lisa A. Carey, MD, FASCO, discusses the phase 3 monarchE trial in hormone receptor–positive, HER2-negative breast cancer.

Completion of Treatment Within 38 Weeks of Breast Cancer Diagnosis Linked With Improved OS

July 22nd 2021

Completion of treatment options such as surgery, chemotherapy, and radiation within 38 weeks from a diagnosis with breast cancer was associated with improved survival in this population.

Understanding Etiology of TNBC is Critical for Discovering Effective Preventive Approaches

July 22nd 2021

Mark E. Sherman, MD, discusses research efforts evaluating immune responses and risk of TNBC and implications for higher rates of disease among African American women.

Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

July 21st 2021

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

PI3KCA Inhibition: Managing AEs in HR+ mBC

July 21st 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.

Using CDK4/6 Inhibitors After HR+ mBC Disease Progression

July 21st 2021

Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.

Dr. Costa Discusses Ongoing Research Efforts in TNBC

July 20th 2021

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.

Leronlimab Plus Carboplatin Showcases Early Signs of OS Benefit in Metastatic TNBC

July 20th 2021

The CCR5 antagonist leronlimab plus carboplatin was shown to result in a 72% decrease in cancer-associated macrophage-like cells, which was linked with an approximate 450% increase in overall survival in 30 patients with metastatic triple-negative breast cancer.

Subcutaneous Therapy for HER2+ Breast Cancer

July 20th 2021

Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.

Safety Profiles of Systemic Therapies for HER2+ MBC

July 20th 2021

Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.

Novel Vaccine Combos Represent a Promising Treatment Approach in Breast Cancer

July 19th 2021

The future of therapeutic vaccines in breast cancer will be dependent on their use in combination with standard anticancer drugs, checkpoint antagonists, and distinct checkpoint inhibitors, Leisha A. Emens, MD, PhD.

Dr. Tolaney on Tailoring HER2-Directed Therapy in Breast Cancer

July 19th 2021

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

FDA Grants Fast Track Status to Trilaciclib Plus Chemo in Locally Advanced or Metastatic TNBC

July 19th 2021

The FDA has granted a fast track designation to trilaciclib for use in combination with chemotherapy in patients with locally advanced or metastatic triple-negative breast cancer

SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer

July 19th 2021

Selective estrogen receptor degraders are becoming increasingly important in the treatment of ER-positive metastatic breast cancer.

Unique Mechanism of Action Positions Plinabulin as a Preventive and Active Therapy in Breast Cancer, NSCLC

July 19th 2021

The highly differentiated mechanism of action of plinabulin, an investigational, first-in-class, selective immunomodulating microtubule binding agent, has positioned the drug as a potential preventive treatment for chemotherapy-induced neutropenia, as well as an anticancer agent in non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE